Form 4: Vertex Pharmaceuticals CEO Reshma Kewalramani Reports Stock Disposal
SEC Form 4 Filing
Reshma Kewalramani, CEO of Vertex Pharmaceuticals, disposed of 9,386 shares of common stock on February 23, 2024, to cover tax obligations.
Summary
- On February 23, 2024, Reshma Kewalramani, the CEO and President of Vertex Pharmaceuticals, disposed of 9,386 shares of the company's common stock.
- The transaction was executed at a price of $431.79 per share.
- Following the transaction, Kewalramani directly owns 136,507 shares of Vertex Pharmaceuticals.
- The disposal was related to covering tax obligations.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a standard transaction (stock disposal for tax obligations) by an insider, which doesn't inherently indicate positive or negative prospects for the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Key Dates
| Date | Description |
|---|---|
| 02/23/2024 | Date of stock disposal transaction |
| 02/27/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.